招股书显示，公司2022年、2023年收入分别为3014.7万美元和5118万美元;分别录得经调整亏损(非国际财务报告准则计量指标)70.8百万美元和67.4百万美元。The world's leading AI-driven biotech company Insisilicon Smart once again submitted a listing application to the Hong Kong Stock Exchange. Morgan Stanley and CICC are co-sponsors
The Zhitong Finance App learned that according to Hong Kong Stock Exchange documents, the world's leading AI-driven biotechnology company Insisilicon Smart has once again submitted a listing application to the Hong Kong Stock Exchange, with Morgan Stanley and CICC as co-sponsors.
Insilicon Smart's business model includes pipeline drug development, drug discovery services, and software solution services. The company's core product ISM001-055 is a small molecule drug candidate that mainly treats fibrosis-related indications by inhibiting TRAF2 and NCK interacting protein kinase (TNIK) (a newly discovered anti-fibrosis target). As of the last practical date, the company has 15 drug candidate pipelines covering fibrosis, oncology, immunology and other treatment fields, 6 of which have obtained IND approval for clinical trials.
According to the prospectus, the company's revenue for 2022 and 2023 was US$30.147 million and US$51.18 million, respectively; adjusted losses (non-IFRS measures) of US$70.8 million and US$67.4 million were recorded, respectively.
